Summary & Overview
CPT 88363: Pathology Selection of Archived Tissue for Molecular Analysis
CPT code 88363 represents a pathologist-conducted review and selection of archived or previously diagnosed tissue for molecular analysis. This preparatory pathology service is critical as molecular testing increasingly guides diagnosis, prognosis, and therapy decisions across oncology and other specialties. Proper identification and selection of optimal tissue can affect test validity and downstream clinical decisions, making this code nationally relevant as molecular diagnostics expand.
Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of what the code covers clinically, typical settings in which it is performed, and the scope of payers considered. The publication summarizes payer coverage patterns and benchmarking where available, highlights policy considerations and coding guidance, and provides clinical context about why specimen selection for molecular testing matters. Where specific payer policies or benchmarks are not available in the input, the report notes that data is not available in the input. The focus is national in scope and intended for clinicians, coding professionals, and policy analysts seeking concise guidance on the role and implications of CPT code 88363.
Billing Code Overview
CPT code 88363 describes a pathologist's procedure to locate, examine, and select archived or previously diagnosed tissue specimens for molecular analysis. This service involves review of existing pathology material to identify appropriate tissue blocks or slides for downstream molecular testing.
-
Service type: Pathology specimen selection and review for molecular testing
-
Typical site of service: Hospital laboratory, independent pathology laboratory, or outpatient surgical pathology setting
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 62-year-old patient with a history of colorectal adenocarcinoma underwent surgical resection and prior pathology. Months later the oncology team requests molecular profiling (e.g., KRAS, NRAS, BRAF, MSI) to guide targeted therapy. The pathologist retrieves archived formalin-fixed, paraffin-embedded (FFPE) tissue blocks or previously diagnosed slides and performs a review to identify and select the most appropriate tumor-rich area for downstream molecular testing. The workflow includes: receipt of the molecular test request, review of prior pathology report and slides, correlation with clinical indication, selection and macrodissection or microdissection if needed, documentation of the selection, and submission of the selected material to the molecular laboratory or referral laboratory for nucleic acid extraction and testing. Typical site of service is the pathology department within a hospital or an independent pathology laboratory. The service type is pathologist-performed specimen selection for molecular analysis, often billed when previously diagnosed tissue is used rather than newly obtained biopsy material.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
26 | Professional component | When billing separates professional interpretation from technical services for the associated molecular test |
TC | Technical component | When billing only the technical component (laboratory processing) of an associated service |
59 | Distinct procedural service | When specimen selection is a distinct service from other procedures performed on the same date |
76 | Repeat procedure by same physician | If the same pathologist repeats the selection procedure during the same episode |
78 | Unplanned return to the OR by same physician | Rarely used; applicable only if selection is related to an unplanned operative return (uncommon for this CPT) |
91 | Repeat clinical diagnostic laboratory test | When a molecular test is repeated on the selected specimen and a repeat-testing modifier is required by payer policy |
52 | Reduced services | If the pathologist performs a partial specimen-selection service compared with the full procedure |
53 | Discontinued procedure | If the selection cannot be completed for clinical reasons and documentation supports discontinuation |
22 | Increased procedural services | When additional work (e.g., extensive microdissection) significantly increases the work beyond typical selection |
90 | Reference (outside) laboratory | When the actual molecular testing is performed by an outside/reference laboratory and billing identifies that relationship |
91 | Repeat clinical diagnostic laboratory test | When testing is repeated; included here because some payers require it for repeat molecular assays |
62 | Co-surgeon | If two pathologists are documented as sharing duties for complex specimen selection |
80 | Assistant surgeon | If an assistant pathologist or physician assists in the selection process and payer policy allows reporting |
| Taxonomy Code | Specialty | Notes |
|---|---|---|
| 207P00000X | Anatomic Pathology | Primary specialty performing tissue review and selection for molecular testing |
| 207K00000X | Clinical Pathology | Involved when coordination with molecular lab and test validation is needed |
| 2080P0200X | Hematopathology | When hematologic malignancy specimens are selected for molecular assays |
| 207LP0101X | Molecular Pathology | Specialty focused on molecular testing and selection of appropriate material |
| 207L00000X | Pathology, General | General pathologists who perform routine specimen selection for molecular testing |
Related Diagnoses
| ICD-10 Code | Description | Clinical Relevance |
|---|---|---|
C18.9 | Malignant neoplasm of colon, unspecified | Archived colorectal tumor tissue frequently selected for molecular profiling to guide chemotherapy or targeted therapy |
C50.911 | Malignant neoplasm of unspecified site of right female breast | Breast cancer specimens are commonly reviewed and selected for ER/PR/HER2 and molecular assays |
C34.90 | Malignant neoplasm of unspecified part of right bronchus or lung | Lung cancer tissue selection is routine for EGFR/ALK/ROS1 and other molecular testing |
C61 | Malignant neoplasm of prostate | Prostate cancer tissue may be selected for genomic testing to inform treatment decisions |
C71.9 | Malignant neoplasm of brain, unspecified | CNS tumor archived tissue selection for molecular profiling can inform prognosis and trial eligibility |
D37.1 | Neoplasm of uncertain behavior of colon | When a prior diagnosis is uncertain, archived tissue selection can support definitive molecular assays |
C25.9 | Malignant neoplasm of pancreas, unspecified | Pancreatic tumor specimens are selected for testing to identify actionable mutations |
C79.51 | Secondary malignant neoplasm of bone | Metastatic deposits on archived blocks may be selected for molecular comparison with the primary tumor |
Related CPT Codes
| CPT Code | Description | Relationship to This Procedure |
|---|---|---|
88305 | Level IV surgical pathology, gross and microscopic examination | Commonly performed before or with selection when initial diagnostic review or additional sectioning is required |
88361 | Histopathology; consultation, including review of slides, when performed for molecular testing (example: laser capture microdissection prep not otherwise specified) | May be billed for specialized slide review or consultation related to selecting tissue for molecular analysis |
88342 | Immunohistochemistry, per specimen; initial single antibody stain | Often performed to confirm tumor content or phenotype before selecting tissue for molecular testing |
81210 | KRAS gene analysis (example molecular code) | Example molecular test that would receive the specimen after selection; selection supports accurate molecular testing |
81275 | BRAF gene analysis | Another molecular assay commonly performed on selected archived tissue to guide therapy |
88312 | Special stains (e.g., mucin, reticulin), each stain | Performed when additional stains are needed to identify tumor regions for selection |